Announcement & Circular
Corporate Governance
Financial Results
Presentations
IR Activities
Contact Us
Announcement & Circular
Stock Information
02186.HK
  (%)
01-17
2022
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF APPLICATION FOR MARKETING AUTHORIZATION IN CHINA FOR OXYCODONE AND NALOXONE EXTENDED-RELEASE TABLETS (LY021702)
Publisher：
01-05
2022
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2021
Publisher：
12-29
2021
ACCEPTANCE OF APPLICATION FOR MARKETING AUTHORIZATION IN CHINA FOR GOSERELIN ACETATE EXTENDED-RELEASE MICROSPHERES FOR INJECTION (LY01005)
Publisher：
12-22
2021
VOLUNTARY ANNOUNCEMENT - LUYE PHARMA GRANTED EXCLUSIVE COMMERCIALIZATION RIGHTS OF RIVASTIGMINE TRANSDERMAL PATCH IN THE MAINLAND OF CHINA TO GENSCI
Publisher：
12-14
2021
VOLUNTARY ANNOUNCEMENT - APPROVAL OBTAINED FOR INITIATING CLINICAL TRIAL FOR THE GROUP'S INNOVATIVE ANTIBODY DRUG BA1201 IN CHINA
Publisher：
12-03
2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2021
Publisher：
11-19
2021
CHANGE OF INFORMATION OF DIRECTOR
Publisher：
11-15
2021
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPLICATION SUBMITTED IN THE U.S. FOR THE GROUP'S NEW DRUG LY03009
Publisher：
11-10
2021
VOLUNTARY ANNOUNCEMENT - LUYE PHARMA GRANTED EXCLUSIVE RIGHTS TO COMMERCIALIZE NEW DRUG RIVASTIGMINE MD IN SWITZERLAND TO ZAMBON
Publisher：
11-03
2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2021
Publisher：
First
1
2
3
4
5
Last
Investors
Announcement & Circular
Corporate Governance
Financial Results
Presentations
IR Activities
Contact Us
Stock Information
02186.HK
  (  %  )
Announcement & Circular
01-17
2022
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF APPLICATION FOR MARKETING AUTHORIZATION IN CHINA FOR OXYCODONE AND NALOXONE EXTENDED-RELEASE TABLETS (LY021702)
01-05
2022
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2021
12-29
2021
ACCEPTANCE OF APPLICATION FOR MARKETING AUTHORIZATION IN CHINA FOR GOSERELIN ACETATE EXTENDED-RELEASE MICROSPHERES FOR INJECTION (LY01005)
12-22
2021
VOLUNTARY ANNOUNCEMENT - LUYE PHARMA GRANTED EXCLUSIVE COMMERCIALIZATION RIGHTS OF RIVASTIGMINE TRANSDERMAL PATCH IN THE MAINLAND OF CHINA TO GENSCI
12-14
2021
VOLUNTARY ANNOUNCEMENT - APPROVAL OBTAINED FOR INITIATING CLINICAL TRIAL FOR THE GROUP'S INNOVATIVE ANTIBODY DRUG BA1201 IN CHINA
12-03
2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2021
11-19
2021
CHANGE OF INFORMATION OF DIRECTOR
11-15
2021
VOLUNTARY ANNOUNCEMENT - CLINICAL TRIAL APPLICATION SUBMITTED IN THE U.S. FOR THE GROUP'S NEW DRUG LY03009
11-10
2021
VOLUNTARY ANNOUNCEMENT - LUYE PHARMA GRANTED EXCLUSIVE RIGHTS TO COMMERCIALIZE NEW DRUG RIVASTIGMINE MD IN SWITZERLAND TO ZAMBON
11-03
2021
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2021
First
1
2
3
4
5
Last